Chloroquine
别名: NSC-187208, CHQ, CQ
中文名称:氯喹
目录号:S6999 Purity: 99.84%
Chloroquine (NSC-187208, CHQ, CQ)是抗疟药和自噬及溶酶体 autophagy/lysosome 的抑制剂。Chloroquine 还可抑制 Toll-like receptor-9 (TLR9) 蛋白的表达。Chloroquine 是非常有效的抗SARS-CoV-2 (COVID-19)侵染剂,在Vero E6细胞中的EC50值为1.13 μM。Chloroquine 也具有抗HIV-1活性。
CAS: 54-05-7
客户使用Selleck的Chloroquine发表文献181篇
- Signal Transduct Target Ther, 2024 9(1):65
- Mol Cancer, 2024 23(1):240
- Cancer Cell, 2022 40(10):1207-1222.e10
- Bioact Mater, 2024 32:277-291
- Nat Commun, 2024 15(1):7522
- Nat Commun, 2024 15(1):2255
- Cancer Commun (Lond), 2024 44(3):408-432
- Adv Sci (Weinh), 2024 11(39):e2400107
- Acta Pharm Sin B, 2024 14(4):1624-1643
- Exp Mol Med, 2024 56(3):686-699
- Theranostics, 2024 14(9):3719-3738
- J Exp Clin Cancer Res, 2024 43(1):248
- Research (Wash D C), 2024 7:0343
- J Adv Res, 2024 S2090-1232(24)00309-6
- J Adv Res, 2024 S2090-1232(24)00106-1
- Clin Transl Med, 2024 14(5):e1686
- MedComm (2020), 2024 5(8):e684
- Cancer Lett, 2024 586:216695
- Basic Res Cardiol, 2024 119(1):113-131
- Int J Biol Sci, 2024 20(15):5939-5958
- Cell Death Dis, 2024 15(11):793
- Cell Death Dis, 2024 15(8):600
- Cell Death Dis, 2024 15(2):175
- Cell Rep, 2024 43(8):114608
- Cell Commun Signal, 2024 22(1):579
- Oncogene, 2024 10.1038/s41388-024-02998-2
- Phytomedicine, 2024 136:156286
- J Med Chem, 2024 67(21):19216-19233
- Cell Death Discov, 2024 10(1):442
- J Anim Sci Biotechnol, 2024 15(1):116
- Cell Death Discov, 2024 10(1):142
- Mol Oncol, 2024 18(9):2277-2297
- Oncogenesis, 2024 13(1):31
- Cells, 2024 13(18)1537
- Cells, 2024 13(11)953
- iScience, 2024 27(8):110598
- iScience, 2024 27(2):108873
- Int J Mol Sci, 2024 25(17)9717
- Int J Mol Sci, 2024 25(1)646
- Biol Direct, 2024 19(1):81
- CNS Neurosci Ther, 2024 30(8):e14913
- J Virol, 2024 98(4):e0164923
- BMC Biol, 2024 22(1):23
- Chin Med, 2024 19(1):52
- Sci Rep, 2024 14(1):30163
- Poult Sci, 2024 103(12):104378
- Life Sci Alliance, 2024 7(6)e202302408
- J Cancer, 2024 15(10):3173-3182
- J Cancer, 2024 15(5):1429-1441
- J Cancer, 2024 15(3):685-698
- Toxicol Appl Pharmacol, 2024 492:117117
- Cancer Biol Ther, 2024 25(1):2431136
- J Cancer Res Clin Oncol, 2024 150(4):218
- Vet Microbiol, 2024 298:110298
- PeerJ, 2024 12:e16691
- Nat Commun, 2023 14(1):6107
- Nat Commun, 2023 14(1):6635
- Nat Commun, 2023 14(1):5242
- Nat Commun, 2023 14(1):3364
- Nat Commun, 2023 14(1):2654
- Nat Commun, 2023 14(1):660
- Cancer Commun (Lond), 2023 10.1002/cac2.12460
- Autophagy, 2023 1-15.
- Redox Biol, 2023 63:102732
- J Pineal Res, 2023 e12855.
- J Nanobiotechnology, 2023 21(1):117
- Pharmacol Res, 2023 192:106789
- Int J Biol Sci, 2023 19(3):950-966
- Cell Death Dis, 2023 14(7):461
- Cell Death Dis, 2023 14(8):488
- Br J Cancer, 2023 10.1038/s41416-023-02435-3
- Cell Rep, 2023 42(10):113211
- Stem Cell Res Ther, 2023 14(1):146
- Cell Death Discov, 2023 9(1):355
- Cell Death Discov, 2023 9(1):316
- Cell Death Discov, 2023 9(1):214
- Anim Nutr, 2023 15:126-136
- mBio, 2023 e0168823.
- Kidney Int Rep, 2023 8(9):1852-1863
- Cells, 2023 12(14)1855
- Front Pharmacol, 2023 14:1264324
- Int Immunopharmacol, 2023 124(Pt B):110915
- Front Pharmacol, 2023 14:1110146
- J Virol, 2023 97(10):e0111523
- J Cell Mol Med, 2023 10.1111/jcmm.17855
- Cancers (Basel), 2023 15(24)5866
- Cancers (Basel), 2023 15(12)3221
- Mol Neurobiol, 2023 10.1007/s12035-023-03355-2
- Transl Oncol, 2023 10.1016/j.tranon.2023.101817
- J Oncol, 2023 2023:2830306
- Oncol Rep, 2023 50(6)216
- Heliyon, 2023 9(7):e17551
- Curr Pharm Des, 2023 29(19):1524-1534
- Oncol Lett, 2023 10.3892/ol.2023.14098
- Hum Exp Toxicol, 2023 42:9603271231161606
- Int Urol Nephrol, 2023 10.1007/s11255-023-03718-7
- Dokl Biochem Biophys, 2023 512(1):292-299
- Cancer Diagn Progn, 2023 3(2):175-182
- Bioact Mater, 2022 18:459-470
- Adv Sci (Weinh), 2022 9(25):e2201701
- Adv Sci (Weinh), 2022 9(28):e2203357
- Acta Pharm Sin B, 2022 12(7):3085-3102
- Theranostics, 2022 12(18):7681-7698
- Redox Biol, 2022 56:102451
- Redox Biol, 2022 52:102292
- Acta Biomater, 2022 S1742-7061(22)00458-5
- BMC Med, 2022 20(1):365
- Sci China Life Sci, 2022 10.1007/s11427-022-2185-9
- Cell Death Dis, 2022 13(6):521
- Cell Death Dis, 2022 13(2):150
- Cell Rep, 2022 41(12):111834
- Cell Commun Signal, 2022 20(1):93
- Phytomedicine, 2022 98:153958
- Biomed Pharmacother, 2022 154:113628
- Biomed Pharmacother, 2022 154:113636
- Cell Biosci, 2022 12(1):167
- J Transl Med, 2022 20(1):434
- Free Radic Biol Med, 2022 193(Pt 1):202-212
- Front Immunol, 2022 13:853194
- mBio, 2022 e0237022.
- Life Sci, 2022 291:120297
- J Mol Liq, 2022 353:118775
- iScience, 2022 25(7):104561
- Front Pharmacol, 2022 13:1002142
- Int J Mol Sci, 2022 23(21)13009
- Pharmaceutics, 2022 14(2)238
- Virulence, 2022 13(1):1407-1422
- Cancers (Basel), 2022 14(13)3225
- Eur J Pharmacol, 2022 924:174970
- J Biol Chem, 2022 S0021-9258(22)01209-1
- Virol J, 2022 19(1):110
- Front Oncol, 2022 12:1025067
- Front Oncol, 2022 12:785345
- Front Oncol, 2022 12:782877
- Biology (Basel), 2022 11(10)1397
- Bone, 2022 154:116262
- BMC Cancer, 2022 22(1):671
- BMC Cancer, 2022 22(1):786
- Biomed Res Int, 2022 2022:9235837
- Biochem Biophys Res Commun, 2022 623:140-147
- Biochem Biophys Res Commun, 2022 606:68-74
- Animals (Basel), 2022 12(22)3070
- Anticancer Agents Med Chem, 2022 22(5):851-863
- Int J Urol, 2022 29(9):1085-1094
- J Orthop Surg Res, 2022 17(1):191
- Tohoku J Exp Med, 2022 10.1620/tjem.2022.J061
- Autophagy, 2021 1-19
- Autophagy, 2021 1-14
- Autophagy, 2021 10.1080/15548627.2021.1912270
- Dev Cell, 2021 56(16):2313-2328.e7
- Clin Transl Med, 2021 11(11):e592
- Cell Death Dis, 2021 12(11):1031
- Cell Biosci, 2021 11(1):124
- Front Immunol, 2021 12:753412
- Front Immunol, 2021 12:685523
- Phytother Res, 2021 10.1002/ptr.7117
- Life Sci, 2021 275:119355
- Biochem Pharmacol, 2021 188:114562
- Biochem Pharmacol, 2021 186:114475
- Int J Mol Sci, 2021 22(24)13630
- Front Cell Dev Biol, 2021 9:670145
- J Virol, 2021 JVI0196021
- Am J Cancer Res, 2021 11(6):2960-2974
- Aging (Albany NY), 2021 13(17):21251-21267
- Virulence, 2021 12(1):509-519
- Front Mol Biosci, 2021 8:789658
- Eur J Pharmacol, 2021 908:174346
- Arthritis Res Ther, 2021 23(1):47
- Front Oncol, 2021 11:650052
- J Immunol, 2021 ji2001404
- Exp Cell Res, 2021 S0014-4827(21)00262-7
- Front Cardiovasc Med, 2021 8:685748
- Med Oncol, 2021 38(10):124
- BMC Pharmacol Toxicol, 2021 22(1):70
- Immunobiology, 2021 226(5):152124
- Anticancer Drugs, 2021 32(6):664-673
- Journal of Shanghai Jiao Tong University, 2021 41(7): 891-897
- bioRxiv, 2020 10.1101/2020.10.13.337774
- Aquat Toxicol, 2018 199:46-54
- Front Cell Infect Microbiol, 2017 7:400
- J Pharmacol Toxicol Methods, 2017 90:39-47
化学信息&溶解度
分子量 | 319.87 |
分子式 | C18H26ClN3 |
CAS号 | 54-05-7 |
Smiles | CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl |
储存条件(自收到货起) | 3年 -20°C 粉状 |
建议分装储备液,避免反复冻融! |
|
体外溶解度 | 批次: |
DMSO : 64 mg/mL ( 200.08 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 64 mg/mL Water : Insoluble DMSO : 64 mg/mL ( 200.08 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 64 mg/mL Water : Insoluble DMSO : 64 mg/mL ( 200.08 mM; DMSO吸湿会降低化合物溶解度,请使用新开封DMSO) Ethanol : 64 mg/mL Water : Insoluble |
体内溶解度 | 批次: |
现配现用,请按从左到右的顺序依次添加,澄清后再加入下一溶剂 | |
5%DMSO
40%PEG300
5%Tween80
50%ddH2O
浓度:3.25mg/ml
(10.16mM)
操作示例:以 1 mL 工作液为例,取50μL65mg/ml的澄清DMSO储备液加到400μL PEG300中,混合均匀使其澄清;向上述体系中加入50μLTween80,混合均匀使其澄清;然后继续加入500μL ddH2O定容至 1 mL。工作液请现配现用!
|
摩尔浓度计算器
质量(g)= 浓度(mol/L)* 体积(L)* 分子量(g/mol)
动物体内配方计算器(澄清溶液)
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系Selleck为您提供正确的澄清溶液配方)
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,注:如该浓度超过该批次药物DMSO溶解度,请先联系Selleck);
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入 μL Tween 80,混匀澄清后加入 μL ddH2O,混匀澄清。
体内配方配制方法:取 μL DMSO母液,加入 μL Corn oil,混匀澄清。
注意:
1. 首先保证母液是澄清的;
2.一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。